Giampaolo Bianchini

12.6k total citations · 4 hit papers
139 papers, 6.5k citations indexed

About

Giampaolo Bianchini is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Giampaolo Bianchini has authored 139 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 65 papers in Cancer Research and 44 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Giampaolo Bianchini's work include HER2/EGFR in Cancer Research (48 papers), Breast Cancer Treatment Studies (40 papers) and Cancer Genomics and Diagnostics (31 papers). Giampaolo Bianchini is often cited by papers focused on HER2/EGFR in Cancer Research (48 papers), Breast Cancer Treatment Studies (40 papers) and Cancer Genomics and Diagnostics (31 papers). Giampaolo Bianchini collaborates with scholars based in Italy, United States and Spain. Giampaolo Bianchini's co-authors include Luca Gianni, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko, Luca Licata, Carmine De Angelis, Lajos Pusztai, Takayuki Iwamoto, Thomas Karn and Gabriel N. Hortobágyi and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Giampaolo Bianchini

128 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2016 2.1k citations Giampaolo Bianchini, Luca Gianni et al. profile →
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

2021 801 citations Giampaolo Bianchini, Carmine De Angelis et al. profile →
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Javier Cortés, Sara A. Hurvitz et al. Nature Medicine profile →

Peers

Countries citing papers authored by Giampaolo Bianchini

Since Specialization

Citations

This map shows the geographic impact of Giampaolo Bianchini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giampaolo Bianchini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giampaolo Bianchini more than expected).

Fields of papers citing papers by Giampaolo Bianchini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giampaolo Bianchini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giampaolo Bianchini. The network helps show where Giampaolo Bianchini may publish in the future.

Co-authorship network of co-authors of Giampaolo Bianchini

This figure shows the co-authorship network connecting the top 25 collaborators of Giampaolo Bianchini. A scholar is included among the top collaborators of Giampaolo Bianchini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giampaolo Bianchini. Giampaolo Bianchini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates 2025 ·Future Oncology ·Winnie Yeo, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal, Hirotoshi Iihara, Eric Roeland, Karin Jordan, Florian Scotté, Lee S. Schwartzberg, Rudolph M. Navari, Matti Aapro, Hope S. Rugo	0
2	Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 2025 ·Clinical Cancer Research ·Luca Licata, (unknown), Giulia Viale, Rebecca Dent, Sara M. Tolaney, Peter Schmid, Erika Hamilton, Christos Sotiriou, Lajos Pusztai, Giampaolo Bianchini	0
3	486MO Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC) 2025 ·Annals of Oncology ·E. Mayer, (unknown), (unknown), W Janni, X. Cynthia, (unknown), Giampaolo Bianchini, Hiroaki Iwata, (unknown), Adam Brufsky, (unknown), Javier Pascual, L. Moreau, (unknown), Nuri Karadurmuş, Cara Arizmendi, Stephen B. Fox, (unknown), Cynthia Huang Bartlett, Nicholas C. Turner	1
4	Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 2025 ·Cancer Treatment Reviews ·Federica Giugliano, (unknown), Barbara Pistilli, Giulia Viale, Giampaolo Bianchini, (unknown), Luca Malorni, Beatrice Taurelli Salimbeni, Angela Espósito, (unknown), Timothy A. Yap, Giuseppe Curigliano, Carmen Criscitiello	3
5	European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study 2025 ·Frontiers in Oncology ·Cristina Saura, Hans Wildiers, Giampaolo Bianchini, José Á. García-Sáenz, Arthur Allignol, (unknown), Markus Lucerna, (unknown), Michelino De Laurentiis	0
6	Prognostic significance of a signature based on senescence-related genes in colorectal cancer 2024 ·GeroScience ·Zoltán Ungvári, Anna Ungvari, Giampaolo Bianchini, Balázs Győrffy	13
7	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ·Journal of Clinical Oncology ·Erika Hamilton, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, (unknown), José Luiz Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, (unknown), Shahid Ashfaque, (unknown), Anton Egorov, Javier Cortés	5
8	Abstract PO3-16-12: European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd 2024 ·Cancer Research ·Michelino De Laurentiis, José Á. García-Sáenz, Giampaolo Bianchini, Cristina Saura, Hans Wildiers, Arthur Allignol, (unknown), Markus Lucerna, (unknown)	2
9	Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial breakdown → 2024 ·Nature Medicine ·Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, Joanne Chiu, (unknown), Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, (unknown), Shahid Ashfaque, (unknown), Anton Egorov, Erika Hamilton	53
10	LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study 2023 ·Annals of Oncology ·Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, A. Antón Torres, Giampaolo Bianchini, (unknown), Stefania Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, (unknown), Hoda Ali, Giuseppe Viale	10
11	Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 2023 ·Cancer Treatment Reviews ·(unknown), Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi	32
12	Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 2023 ·Cancer Treatment Reviews ·Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Criscitiello	36
13	Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study breakdown → 2022 ·Annals of Oncology ·Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, (unknown), Pinuccia Valagussa, Giuseppe Viale	204
14	ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 2022 ·Future Oncology ·Sara A. Hurvitz, Thomas Bachelot, Giampaolo Bianchini, Nadia Harbeck, Sherene Loi, Yeon Hee Park, Aleix Prat, Leslie Gilham, Thomas Boulet, (unknown), Estefanía Monturus, Chiara Lambertini, (unknown), Adam Knott, Eleonora Restuccia, Peter Schmid	15
15	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 2019 ·European Journal of Cancer ·(unknown), Giampaolo Bianchini, Michiko Ando, (unknown), Daiki Kobayashi, Carmen Criscitiello, Giuseppe Curigliano, Takayuki Iwamoto, Naoki Niikura, Hiroyuki Takei, Atsushi Yoshida, Junko Takei, Koyu Suzuki, Hideko Yamauchi, Naoki Hayashi	59
16	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 2017 ·Cancer Research ·Anton Safonov, Tingting Jiang, Giampaolo Bianchini, Balázs Győrffy, Thomas Karn, Christos Hatzis, Lajos Pusztai	108
17	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 2015 ·Cancer Discovery ·Francesca Cottini, Teru Hideshima, Rikio Suzuki, Yu‐Tzu Tai, Giampaolo Bianchini, Paul G. Richardson, Kenneth C. Anderson, Giovanni Tonon	87
18	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers 2011 ·Clinical Cancer Research ·Charles Coutant, Roman Rouzier, Yuan Qi, Jacqueline Lehmann‐Che, Giampaolo Bianchini, Takayuki Iwamoto, Gabriel N. Hortobágyi, W. Fraser Symmans, Serge Uzan, Fabrice André, Hugues de Thé, Lajos Pusztai	44
19	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer 2010 ·Cancer Research ·Giampaolo Bianchini, Takayuki Iwamoto, Yuan Qi, Charles Coutant, Christine Y. Shiang, (unknown), Libero Santarpia, Vicente Valero, Gabriel N. Hortobágyi, W. Fraser Symmans, Luca Gianni, Lajos Pusztai	53
20	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers 2010 ·Cancer ·Catherine M. Kelly, Savitri Krishnamurthy, Giampaolo Bianchini, Jennifer K. Litton, Ana M. Gonzalez‐Angulo, Gabriel N. Hortobágyi, Lajos Pusztai	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact